Platform Technologies

Nanosponge Drug Delivery Systems

Nanosponges are a cutting-edge development in drug delivery technology. Submicroscopic particles made of biocompatible materials like lipids, Dendrimers, or polymers.

Nanosponges are distinctive because of their porous structure, which enables them to absorb medications into their cavities. These structures can encapsulate a diverse range of pharmaceuticals, such as proteins, antibodies, biocatalysts, vaccines, hydrophilic and hydrophobic chemicals, and many other medications.

Nano-sized sponges can encapsulate medicinal chemicals and precise chemical “linkers” to form covalent interactions with certain cells. Nanosponges are defined by their complex structure consisting of small mesh-like formations at the nanoscale, formed by polymers covalently bonded with cross-linkers. Upon reaching the target cells, they either attach to or enter the cell, releasing therapeutic chemicals in a predictable and regulated way.

The performance of nanosponges can be affected by the choice of polymers utilized in their manufacturing process, primarily due to cross-linking.  The particle size of nanosponges can be controlled by adjusting the proportion of cross-linker to polymer. Nanosponges can be delivered through several routes including oral, topical, parenteral, and inhalation for the administration of encapsulated medicines.

A Vision Powered By Collaboration

Nanoparticular Drug Delivery Systems

Nano particles are currently being utilized in drug delivery systems due to their distinct physicochemical properties and biological behaviors. The nanoparticle shows the capacity to deliver drugs specifically to a targeted destination. Nanoparticles can transport bioactive compounds, growth factors and genes.

Nanoparticles possess distinct features compared to traditional carrier materials which can transport active chemicals more securely and efficiently than standard drug carrier systems. Nanoparticles frequently exhibit a superior loading rate. In order to facilitate the delivery of medication for a longer period of time, nanoparticles can be made to release their payload in a controlled manner.

Phytosome Drug Delivery System For Natural & Cosme Ceutical Compounds

Plants have been used as traditional medicine since ancient times for treating the diseases, metabolite active compounds from plants have excellent bioactivity, and pharmacological properties  . However, these compounds have physicochemical limitations in terms of its poor solubility and penetration into the cells membrane. Phytosome drug delivery system can be the primary choice to improve the physicochemical properties, which allows increasing the effectiveness. The phytosome drug delivery system becomes a promising modification technique for natural compounds due to the ability to improve the physicochemical properties and increase the effectiveness.  Phytosome is a nanoparticle delivery system composed of monolayer or double-layer phospholipids which form vesicle and is used for the delivery of polar or nonpolar natural compounds. The phospholipid content in this system is able to mediate the increase in solubility by hydrogen-bonding interaction between water molecules with phosphate groups in double-layer system of phytosome carrier and improve permeability of the active compounds by phospholipid deformation of cells membrane with phytosome carrier. Currently, the use of phytosome has been carried out for modification of natural ingredients compounds intended to improve its effectiveness.

Patient Derived Xenografts(PDX)

These are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse.

[1] It is a form of xenotransplantation. PDX models are used to create an environment that allows for the continued growth of cancer after its removal from a patient. In this way, tumor growth can be monitored in the laboratory, including in response to potential therapeutic options.[1] Cohorts of PDX models can be used to determine the therapeutic efficiency of a therapy against particular types of cancer, or a PDX model from a specific patient can be tested against a range of therapies in a ‘personalized oncology’ approach.

Patient Derived Tumor Organoids (PDTO)

Tumor heterogeneity is a serious problem in cancer treatment since it frequently leads to therapeutic resistance and tumor recurrence. Commonly used tumor models such as patient derived xenografts (PDX) and Patient-derived tumor cells (PDT) have several disadvantages. Recent developments in 3D organoid culture technology have represented an alternate model that mimics the tissue physiological environment in a dish. The use of organoid technology in oncology has various advantages in terms of speeding up cancer research. Patient-derived tumor organoids (PDTOs) cover voids in PDT and PDX models due to their pathophysiological similarities to natural metastasis and carcinogenesis.

 PDTOs can be used as an approach for drug assessment techniques, and discovery of prognostic biomarkers and mechanisms of resistance to tailor the personalized patient’s therapy to combat cancer resistance and recurrence. Similarly, the technology can also be utilized for bio banking and further used for the discovery of novel anti-cancer molecules and validation of FDA approved drugs that have potential for repurposing in cancer therapy. This will offer up novel treatment options and lengthen the life longevity of cancer patients.